Published in Patient on January 01, 2013
Patient preferences and satisfaction in a multispecialty infusion center. Patient Prefer Adherence (2014) 0.75
Examining systemic steroid Use in older inflammatory bowel disease patients using hurdle models: a cohort study. BMC Pharmacol Toxicol (2015) 0.75
Preferences Regarding Shared Decision-Making in Japanese Inflammatory Bowel Disease Patients. Adv Ther (2016) 0.75
Shared decision-making for biologic treatment of autoimmune disease: influence on adherence, persistence, satisfaction, and health care costs. Patient Prefer Adherence (2017) 0.75
Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med (2005) 14.50
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet (2002) 14.14
Patient-centredness: a conceptual framework and review of the empirical literature. Soc Sci Med (2000) 12.87
Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med (2010) 12.35
The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut (2001) 10.07
Patient-centered medicine. A professional evolution. JAMA (1996) 7.39
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology (2006) 6.88
Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med (2005) 5.36
Conjoint analysis applications in health--a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health (2011) 5.12
Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet (2009) 5.03
Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology (2011) 4.88
Measuring numeracy without a math test: development of the Subjective Numeracy Scale. Med Decis Making (2007) 4.80
Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med (2007) 4.56
Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med (2007) 4.39
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology (2004) 4.26
Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol (2006) 4.18
A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology (2005) 4.06
Bridging the gap. The separate worlds of evidence-based medicine and patient-centered medicine. Patient Educ Couns (2000) 3.94
Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut (2005) 3.86
Ileal pouch-anal anastomoses complications and function in 1005 patients. Ann Surg (1995) 3.85
Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology (1994) 3.81
The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology (2001) 3.60
Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology (2008) 3.52
The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology (2004) 3.50
Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology (2004) 3.40
A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. Am J Gastroenterol (2002) 3.31
Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol (2009) 3.26
Validation of the Subjective Numeracy Scale: effects of low numeracy on comprehension of risk communications and utility elicitations. Med Decis Making (2007) 2.89
Risks and benefits of infliximab for the treatment of Crohn's disease. Clin Gastroenterol Hepatol (2006) 2.88
Influence of data display formats on physician investigators' decisions to stop clinical trials: prospective trial with repeated measures. BMJ (1999) 2.87
Using conjoint analysis to assess women's preferences for miscarriage management. Health Econ (1997) 2.87
Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. Value Health (2013) 2.82
A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med (2000) 2.78
Design features of graphs in health risk communication: a systematic review. J Am Med Inform Assoc (2006) 2.73
Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol (2009) 2.72
Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol (2004) 2.65
Reducing the influence of anecdotal reasoning on people's health care decisions: is a picture worth a thousand statistics? Med Decis Making (2005) 2.43
The impact of the format of graphical presentation on health-related knowledge and treatment choices. Patient Educ Couns (2008) 2.42
Postoperative mortality and morbidity in French patients undergoing colorectal surgery: results of a prospective multicenter study. Arch Surg (2005) 2.39
Measuring preferences for health care interventions using conjoint analysis: an application to HIV testing. Health Serv Res (2002) 2.36
Information needs and preferences of recently diagnosed patients with inflammatory bowel disease. Inflamm Bowel Dis (2011) 2.31
Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis (2010) 2.20
Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology (2009) 2.09
Making numbers matter: present and future research in risk communication. Am J Health Behav (2007) 2.05
Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. Am J Gastroenterol (2007) 2.05
Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. Ann Intern Med (1991) 2.03
Addressing literacy and numeracy to improve diabetes care: two randomized controlled trials. Diabetes Care (2009) 1.88
Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease. Am J Gastroenterol (2009) 1.86
Immunosuppressant medications and mortality in inflammatory bowel disease. Am J Gastroenterol (2008) 1.80
Assessing values for health: numeracy matters. Med Decis Making (2001) 1.78
Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev (2009) 1.74
Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology (2007) 1.71
Multiple sclerosis patients' benefit-risk preferences: serious adverse event risks versus treatment efficacy. J Neurol (2009) 1.67
Patient-centered medicine and patient-oriented research: improving health outcomes for individual patients. BMC Med Inform Decis Mak (2013) 1.66
Cost-utility of initial medical management for Crohn's disease perianal fistulae. Gastroenterology (2001) 1.63
Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am J Gastroenterol (1993) 1.61
Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol (2005) 1.59
Patients and doctors--evolution of a relationship. N Engl J Med (2012) 1.58
Quality of life of patients with ulcerative colitis preoperatively and postoperatively. Gastroenterology (1991) 1.57
Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis. Gastroenterology (2008) 1.56
Comparison of time-tradeoff utilities and rating scale values of cancer patients and their relatives: evidence for a possible plateau relationship. Med Decis Making (1995) 1.55
Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology (2010) 1.54
Conventional medical management of inflammatory bowel disease. Gastroenterology (2011) 1.53
Can the standard gamble be used to determine utilities for uncertain health states? An example using postoperative maintenance therapy in Crohn's disease. Med Decis Making (2000) 1.51
Screening differences and risk of cervical cancer in inflammatory bowel disease. Aliment Pharmacol Ther (2008) 1.50
Willingness to pay for improved respiratory and cardiovascular health: a multiple-format, stated-preference approach. Health Econ (2000) 1.48
What are the chances? Evaluating risk and benefit information in consumer health materials. J Med Libr Assoc (2004) 1.41
High-risk individuals' willingness to pay for diabetes risk-reduction programs. Diabetes Care (2006) 1.41
Long-term functional results after ileal pouch anal restorative proctocolectomy for ulcerative colitis: a prospective observational study. Ann Surg (2003) 1.40
Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am J Gastroenterol (2011) 1.39
Prospective, age-related analysis of surgical results, functional outcome, and quality of life after ileal pouch-anal anastomosis. Ann Surg (2003) 1.39
Numeracy and communication with patients: they are counting on us. J Gen Intern Med (2008) 1.38
Mortality and causes of death in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark. Gastroenterology (2002) 1.37
Mortality in patients with and without colectomy admitted to hospital for ulcerative colitis and Crohn's disease: record linkage studies. BMJ (2007) 1.34
Trends in hospitalization rates for inflammatory bowel disease in the United States. Clin Gastroenterol Hepatol (2007) 1.30
Review article: practical management of inflammatory bowel disease patients taking immunomodulators. Aliment Pharmacol Ther (2005) 1.20
Integrating anti-tumor necrosis factor therapy in inflammatory bowel disease: current and future perspectives. Am J Gastroenterol (2001) 1.19
Ileal pouch surgery for ulcerative colitis. World J Gastroenterol (2007) 1.15
Communicating treatment risk reduction to people with low numeracy skills: a cross-cultural comparison. Am J Public Health (2009) 1.15
Do patient preferences influence decisions on treatment for patients with steroid-refractory ulcerative colitis? Clin Gastroenterol Hepatol (2006) 1.14
Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update. J Pediatr Gastroenterol Nutr (2009) 1.14
Are adult patients more tolerant of treatment risks than parents of juvenile patients? Risk Anal (2008) 1.13
Patient perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease. Inflamm Bowel Dis (2008) 1.13
Are gastroenterologists less tolerant of treatment risks than patients? Benefit-risk preferences in Crohn's disease management. J Manag Care Pharm (2010) 1.11
An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. The Mesalamine Study Group. Ann Intern Med (1996) 1.11
QALYs: some challenges. Value Health (2009) 1.10
How do patients with inflammatory bowel disease want their biological therapy administered? BMC Gastroenterol (2010) 1.09
Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev (2010) 1.07
Hepatosplenic gamma/delta T-cell lymphoma in immunocompromised patients. Report of two cases and review of literature. Am J Clin Pathol (2001) 1.03
Inflammatory bowel disease: patients' expectations in the 1990s. J R Soc Med (1991) 1.01
Treatment of inflammatory bowel disease with azathioprine and 6-mercaptopurine. Gastroenterol Clin North Am (2004) 0.98
Subtotal colectomy for severe acute colitis: a 20-year experience of a tertiary care center with an aggressive and early surgical policy. J Am Coll Surg (2003) 0.97
Colectomy rate in steroid-refractory colitis initially responsive to cyclosporin: a long-term retrospective cohort study. BMC Gastroenterol (2007) 0.97
Urgent subtotal colectomy for severe inflammatory bowel disease. Dis Colon Rectum (2005) 0.96
Crohn's disease and ulcerative colitis are associated with elevated standardized mortality ratios: a meta-analysis. Inflamm Bowel Dis (2013) 0.96
Views of treatment decision making from adolescents with chronic illnesses and their parents: a pilot study. Health Expect (2008) 0.95
The information needs and preferences of persons with longstanding inflammatory bowel disease. Can J Gastroenterol (2012) 0.94
Educational inequalities in patient-centred care: patients' preferences and experiences. BMC Health Serv Res (2012) 0.94
When should ulcerative colitis patients undergo colectomy for dysplasia? Mismatch between patient preferences and physician recommendations. Inflamm Bowel Dis (2010) 0.93
Perceived and actual quality of life with ulcerative colitis: a comparison of medically and surgically treated patients. Am J Gastroenterol (2011) 0.92
Conjoint analysis applications in health--a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health (2011) 5.12
Measuring preferences for health care interventions using conjoint analysis: an application to HIV testing. Health Serv Res (2002) 2.36
Conjoint Analysis Applications in Health - How are Studies being Designed and Reported?: An Update on Current Practice in the Published Literature between 2005 and 2008. Patient (2010) 2.30
Measuring patient preferences for colorectal cancer screening using a choice-format survey. Value Health (2007) 1.86
Measuring what people value: a comparison of "attitude" and "preference" surveys. Health Serv Res (2002) 1.75
How do physician assessments of patient preferences for colorectal cancer screening tests differ from actual preferences? A comparison in Canada and the United States using a stated-choice survey. Health Econ (2009) 1.27
Mothers' preferences and willingness to pay for vaccinating daughters against human papillomavirus. Vaccine (2009) 1.09
Patient preferences for surgical versus medical therapy for ulcerative colitis. Inflamm Bowel Dis (2014) 1.05
Risking health to avoid injections: preferences of Canadians with type 2 diabetes. Diabetes Care (2005) 1.04
Stated preferences of patients with cancer for health-related quality-of-life (HRQOL) domains during treatment. Qual Life Res (2006) 0.96
Benefits, risk, and uncertainty: preferences of antiretroviral-naïve African Americans for HIV treatments. AIDS Patient Care STDS (2009) 0.96
Hypothetical bias, cheap talk, and stated willingness to pay for health care. J Health Econ (2009) 0.94
Estimating older adults' preferences for walking programs via conjoint analysis. Am J Prev Med (2009) 0.94
Editorial: Moving the QALY forward or just stuck in traffic? Value Health (2009) 0.86
Patients' benefit-risk preferences for chronic idiopathic thrombocytopenic purpura therapies. Ann Pharmacother (2010) 0.85
How do physicians weigh benefits and risks associated with treatments in patients with osteoarthritis in the United Kingdom? J Rheumatol (2012) 0.85
Einstein on willingness to pay per QALY: is there a better way? Med Decis Making (2005) 0.85
Eliciting benefit-risk preferences and probability-weighted utility using choice-format conjoint analysis. Med Decis Making (2011) 0.84
Quantifying asthma patient preferences for onset of effect of combination inhaled corticosteroids and long-acting beta2-agonist maintenance medications. Allergy Asthma Proc (2009) 0.84
Economic evaluation of the benefits of reducing acute cardiorespiratory morbidity associated with air pollution. Environ Health (2002) 0.83
Using the incremental net benefit framework for quantitative benefit-risk analysis in regulatory decision-making--a case study of alosetron in irritable bowel syndrome. Value Health (2009) 0.83
Physician preferences for extra-glycemic effects of type 2 diabetes treatments. Diabetes Ther (2013) 0.82
Healthy-days time equivalents for outcomes of acute rotavirus infections. Vaccine (2011) 0.81
Who pays attention in stated-choice surveys? Health Econ (2010) 0.79
Estimating importance weights for the IWQOL-Lite using conjoint analysis. Qual Life Res (2010) 0.79
Patient preferences and linear scoring rules for patient-reported outcomes. Patient (2010) 0.78
Understanding the relative importance of preserving functional abilities in Alzheimer's disease in the United States and Germany. Qual Life Res (2014) 0.78
Physicians' stated trade-off preferences for chronic hepatitis B treatment outcomes in Germany, France, Spain, Turkey, and Italy. Eur J Gastroenterol Hepatol (2012) 0.77
Adolescent girls' preferences for HPV vaccines: a discrete choice experiment. Adv Health Econ Health Serv Res (2014) 0.77
Caregiver Preferences for the Treatment of Males with Fragile X Syndrome. J Dev Behav Pediatr (2016) 0.76
Older Americans' risk-benefit preferences for modifying the course of Alzheimer disease. Alzheimer Dis Assoc Disord (2009) 0.76
Modeling for health care and other policy decisions: uses, roles, and validity. Value Health (2002) 0.75
Evaluating migraineurs' preferences for migraine treatment outcomes using a choice experiment. Headache (2013) 0.75